Choreo LLC’s Taysha Gene Therapies TSHA Stock Holding History

Choreo LLC’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$72.3K	Buy	10,618 +574	+6%	+$3.4K	﹤0.01%	1629
2026 Q1	$44.9K	Buy	+10,044	New	+$46.7K	﹤0.01%	1570

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Choreo LLC's TSHA Position: Q2 2026 in Review

Choreo LLC increased its Taysha Gene Therapies (TSHA) stake by 5.7% in Q2 2026, buying an estimated $3.4K and bringing the position to 10,618 shares worth $72.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1629.

Choreo LLC first reported a position in TSHA in Q1 2026 and has held it in 2 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Choreo LLC held 10,618 shares of Taysha Gene Therapies worth $72.3K as of Q2 2026.
Choreo LLC bought 574 Taysha Gene Therapies shares in Q2 2026, an estimated $3.4K.
Taysha Gene Therapies made up ﹤0.01% of Choreo LLC's portfolio in Q2 2026, its #1629 holding.
Choreo LLC first reported a position in Taysha Gene Therapies in Q1 2026 and has held it in 2 quarters since.
209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Choreo LLC's 13F filing for Q2 2026, filed 4 Aug 2026.